Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 10/20 | 0.38 |
| ▸ | GSK3B | P49841 | 4/20 | 0.38 |
| ▸ | HTR2A | P28223 | 4/20 | 0.38 |
| ▸ | PIM1 | P11309 | 2/20 | 0.37 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.37 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.37 |
| ▸ | MET | P08581 | 1/20 | 0.37 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.37 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26669762 | 1.00 | CYP2C19 (0.47) | CYP2C19HTR2CGSK3BHTR2APIM1 | |
| SCHEMBL21098425 | 1.00 | CYP2C19 (0.47) | CYP2C19HTR2CGSK3BHTR2APIM1 | |
| Hydrochloric Acid SCHEMBL30619116 | 0.99 | CYP2C19 (0.46) | CYP2C19HTR2CGSK3BHTR2APIM1 | |
| SCHEMBL31045848 | 0.80 | HTR2C (0.40) | HTR2CGSK3BHTR2APIM1PIM3 | |
| SCHEMBL17884822 | 0.80 | MMP2 (0.42) | HTR2CGSK3BHTR2APIM1PIM3 | |
| SCHEMBL21098718 | 0.78 | ALOX5 (0.48) | HTR2CHTR2APIM1PIM3PIM2 | |
| SCHEMBL21098721 | 0.78 | ALOX5 (0.48) | HTR2CHTR2APIM1PIM3PIM2 | |
| SCHEMBL21098921 | 0.77 | HTR2C (0.44) | HTR2CGSK3BHTR2APIM1PIM3 | |
| SCHEMBL21098920 | 0.77 | HTR2C (0.44) | HTR2CGSK3BHTR2APIM1PIM3 | |
| SCHEMBL21098363 | 0.77 | GSK3B (0.42) | HTR2CGSK3BHTR2ACYP17A1HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3498715-B1 | ANTI-HCMV VIRUS COMPOUND | MEDSHINE DISCOVERY INC (CN) | 2021-06-09 | — | — | EP | disclosed |
| US-10851112-B2 | Anti-HCMV virus compound | MEDSHINE DISCOVERY INC. (CN) | 2020-12-01 | — | — | US | disclosed |
| US-20190202838-A1 | ANTI-HCMV VIRUS COMPOUND | PHAENO THERAPEUTICS CO., LTD. (CN) | 2019-07-04 | — | — | US | disclosed |
| EP-3498715-A1 | ANTI-HCMV VIRUS COMPOUND | Medshine Discovery Inc. (CN) | 2019-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190202838-A1 | ANTI-HCMV VIRUS COMPOUND | RPL35, RPL5, RPL17 | CYP2C19 1598/4885HTR2C 4587/4885GSK3B 2415/4885 |
| US-10851112-B2 | Anti-HCMV virus compound | RPL35, RPL5, RPL17 | CYP2C19 1598/4885HTR2C 4587/4885GSK3B 2415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.